4960 PEACHTREE INDUSTRIAL BOULEVARD, NORCROSS, GA
Reports June 30, 2026 Financial Results and Provides Business Update
Announces Conversion of $105.8 Million in Debt to Equity, Significantly Strengthening Balance Sheet
Announces Positive Type C Meeting with the FDA for Belapectin in Patients with MASH Cirrhosis and Portal Hypertension
Reports March 31, 2026 Financial Results and Provides Business Update
Financial Results, Press Release
Strengthens Board of Directors with Appointment of Henry Brem, M.D.
Retention Bonuses Approved for CMO Dr. Khurram Jamil and CFO Jack Callicutt
Director Resignation - Marc Rubin Steps Down from Galectin Therapeutics Board
Q2
Q1
FY 2025
Q3
FY 2024
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Correspondence
Submission Upload
Free Writing Prospectus
Prospectus Filed Pursuant to Rule 424(b)(1)